Clinical Trial

A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to investigate the safety and tolerability of LY4298445 in healthy participants and in participants with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). Participation in the study will last up to approximately 52 weeks.
Protocol Amendment History 2 changes
notable Trial sites expanded: 1 -> 8 locations 2026-06-24
notable Trial sites reduced: 7 -> 1 locations 2026-06-05
Trial Details
NCT Number NCT07276958
Lead Sponsor Eli Lilly and Company
Conditions Healthy, Systemic Lupus Erythematosus, Rheumatoid Arthritis
Enrollment 63 participants
Start Date 2026-02-04
Primary Completion 2028-03 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-17